Periodontal Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: April 14, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.2 billion |
|
Market Size Value in 2031 |
US$ 4.5 billion |
|
CAGR |
8.3% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global periodontal therapeutics market was valued at US$ 2.2 billion in 2022 and is expected to register a revenue CAGR of 8.3% to reach US$ 4.5 billion by 2031.
Periodontal Therapeutics Market Fundamentals
Periodontal diseases affect the gums, periodontal ligaments, and alveolar bone, which support and surround the teeth. Inflammation, bleeding gums, bone loss, and tooth loss are symptoms of periodontal diseases like gingivitis and periodontitis, which are brought on by bacterial infections. If left untreated, these conditions can lead to tooth loss. Periodontitis is a long-lasting bacterial illness brought on by microbial plaque, sometimes called gum disease, which has colonized the tooth surface and the area beneath the gingival margin. Smoking, hormonal fluctuations, poor dental hygiene, and a few inherited factors are the main causes of periodontal disorders. Antibiotics are often used as adjunctive therapy in treating periodontal diseases to control bacterial infections. Common antibiotics used in periodontal therapeutics include metronidazole, amoxicillin, and doxycycline. Various oral rinses and mouthwashes containing antimicrobial agents, such as chlorhexidine, hydrogen peroxide, and essential oils, are adjunctive therapies to reduce plaque and gingival inflammation.
[67866]
Periodontal Therapeutics Market Dynamics
Periodontal diseases, such as gingivitis and periodontitis, continue to be prevalent globally, affecting millions. This has increased the demand for periodontal therapeutics to manage and treat these conditions. According to the WHO Report 2023, there are projected to be more than 1 billion severe periodontal diseases globally, affecting about 19% of the adult population. Poor dental hygiene and cigarette use are the main causes of periodontal disease. Advancements in dental technology have led to the development of innovative periodontal therapeutics, such as laser-based treatments, tissue engineering, and regenerative therapies. In March 2023, Sigrid Therapeutics launched its SiPore® technology for guarding against gum disease and dental cavities. SiPore® is a patented technology that may be added to toothpaste, mouthwash, and other products to reduce oral bacteria’s access to carbohydrates and their capacity to produce dental biofilm. It was created as one of the most significant advancements since fluoride. These technologies offer less invasive and more effective treatment options for periodontal diseases, driving the revenue growth of the global periodontal therapeutics market. Increased awareness about the importance of oral health and the link between oral health and overall health has resulted in higher patient awareness and treatment for periodontal diseases. This has contributed to the growth of the global periodontal therapeutics market as patients are more proactive in managing their oral health. Personalized medicine, including tailored treatment plans based on individual patient characteristics, is gaining traction in dentistry, including periodontal therapeutics. With advances in genetic testing and precision medicine, periodontal therapeutics customized to an individual’s unique oral health needs and genetic profile are becoming more prominent, leading to improved treatment outcomes. The sale of Quince Therapeutics, Inc.’s historical small molecule protease inhibitor portfolio, which included COR588, COR388, COR852, and COR803, was announced in January 2023. The Phase 2-ready lead chemical, COR588, is a selective oral small molecule inhibitor of lysine-gingipain that is being further tested for the treatment of Alzheimer’s disease in patients with mild to severe dementia and biomarker evidence of P. gingivalis (an important pathogenic bacteria for periodontal disease) infection. Small molecule inhibitors that precisely target gingipains are a novel therapeutic strategy for treating P. gingivalis, a bacteria linked to dementia and other degenerative and inflammatory diseases. There is a continuous focus on research and development in periodontal therapeutics to explore new treatment modalities, formulations, and technologies. This includes developing novel drug delivery systems, antimicrobial agents, and regenerative therapies. With increasing evidence of the role of biologics in dental health, the focus is on promoting biologic agents for periodontal regeneration. For instance, in July 2021, Cortexyme, Inc. launched new preclinical data demonstrating effective dose range finding data for its lead drug candidate atuzaginstat (COR388) in periodontal disease, as well as its participation in the 2021 General Session & Exhibition of the International Association for Dental Research (IADR), an online conference. Such ongoing research and development efforts are expected to drive the growth of the global periodontal therapeutics market revenue with new and improved treatment options.
However, many factors are hindering the revenue growth of the global periodontal therapeutics market. Periodontal therapeutics can involve various interventions, such as scaling and root planning, antibiotic therapy, and surgical procedures, which can be expensive. The cost of treatment may be a barrier for some patients, particularly those without insurance coverage or limited financial resources, and may impact the uptake of periodontal therapeutics. Additionally, periodontal diseases are often considered less serious than other oral health conditions, such as cavities or tooth loss, and may receive a different level of awareness and education. This can result in lower demand for periodontal therapeutics, as patients may need to be fully informed about the importance of treating and managing periodontal diseases.
Periodontal Therapeutics Market Ecosystem
The global periodontal therapeutics market is analyzed from three perspectives: drug type, distribution channel, and region.
Periodontal Therapeutics Market by Drug Type
[68686]
Based on drug types, the global periodontal therapeutics market is segmented into systemic antibiotics, local antibiotics, and other drug types. The systemic antibiotics segment is further sub-segmented into doxycycline, minocycline, and metronidazole. The local antibiotics segment is further segmented into atridox, periochip, and arestin.
The local antibiotics segment is expected to grow at a high revenue CAGR in the global periodontal therapeutics market during the forecast period. The global periodontal therapeutics market revenue is expected to grow using local antibiotics to treat periodontal disease. The preference for site-specific distribution, low dose requirements, and reduced side effects over systemic drug delivery methods, which result in superior therapeutic outcomes, is increasing, helping local antibiotics flourish. It also offers a safe and efficient way of therapy, and due to several benefits, it is anticipated to dominate the market in the next years. These local antibiotics are most frequently administered as mouth rinses, gels, or tiny chips placed into the gingival sulcus. Chlorhexidine is an antibacterial used to reduce gingivitis and plaque in periodontal pockets or the mouth (marketed under the prescription-only brand names Peridex, PerioChip, PerioGard, Denti-Rinse, Paroex, and Acclean). For instance, Medicom, Denti-Care Denti-Rinse Chlorhexidine Oral Rinse Gluconate mint boosts tissue inflammation and bleeding and is great for periodontitis and oral irrigation.
Periodontal Therapeutics Market by Distribution Channel
Based on the distribution channel, the global periodontal therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others.
The hospital pharmacies segment accounts for the largest global periodontal therapeutics market revenue share. This is due to a large number of prescribed medicines sold in hospital pharmacies and prescribed by dental professionals.
Retail pharmacies also account for a significant revenue share of the global periodontal therapeutics market. Some periodontal therapeutics, such as oral medications or over-the-counter (OTC) products, are distributed through retail pharmacies. These products may be available for patients without a prescription or may be recommended by dental professionals for at-home use.
With the rise of e-commerce, online channels have also become a significant part of the distribution channel for periodontal therapeutics. Manufacturers, distributors, and retailers may sell periodontal therapeutics through their online platforms, allowing for convenient access and purchase of these products.
Periodontal Therapeutics Market by Region
Based on region, the global periodontal therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the most significant global periodontal therapeutics market revenue share. It is mostly related to the rising number of diabetics, geriatrics, and patients with periodontal illnesses in the area. The rise in healthcare spending, sophisticated healthcare infrastructure, high level of drug development, well-established market players, high investment in R&D activities by key players, and a suitable regulatory framework for periodontal drugs contribute to the region’s market revenue share growth. The United States currently controls the North American periodontal therapies market revenue share. The CDC estimates that 50 percent of people aged thirty and older have periodontitis, a more serious form of periodontal disease. The population of the United States is approximately 64.7 million. Also, the study found that moderate to severe periodontitis affected 64% of participants aged 65 and beyond. Over the next 40 years, there will be a significant increase in the number of Americans 65 and older, reaching 80 million in 2040. Between 2000 and 2040, the population of adults aged 85 and over will nearly double. The market for periodontal therapeutics is thus expected to grow due to the aging population and the rising number of people suffering from periodontal disorders.
The periodontal therapeutics market in the Asia Pacific is expected to grow at a high revenue CAGR during the forecast period. In Japan, periodontitis is common, with chronic periodontitis affecting most individuals. In addition, it is now the main reason for tooth loss in the nation’s adult population. Diagnostic and therapeutic procedures are significantly underwritten by health insurance. However, some procedures like implant surgeries and services like dental checkups are not covered. Yet, standard non-surgical periodontal therapy has demonstrated the ability to enhance a patient’s perception of their dental health. Consequently, the frequency of periodontal diseases and the country’s aging population rise present potential for the Japanese periodontal therapeutics market.
In developing countries like India, periodontal disease is a common oral condition. The adult population’s poor oral hygiene is mostly to blame for the rise in dental caries and periodontal disorders. In addition, a lot of people have periodontal conditions, with periodontitis being one of the main reasons for tooth loss. Thus, it is necessary to implement appropriate initiatives to improve India’s oral hygiene to lower the prevalence of periodontal disease. For instance, OCare has offered quality dental treatment to individuals nationwide by introducing India’s first dental insurance plan in villages. Hence, there is an urgent need for the country to have an oral health policy and dental health planners who can understand and formulate effective oral health policies. Nevertheless, these factors mentioned above have contributed significantly to the progress of India’s periodontal therapeutics market revenue.
Competitive Landscape of the Periodontal Therapeutics Market
The prominent players operating in the global periodontal therapeutics market are: -
Strategic Developments in the Periodontal Therapeutics Market
The expected size of the global periodontal therapeutics market in 2031 is US$ 4.5 billion.
The expected revenue CAGR for the periodontal therapeutics market is 8.3% during the forecast period.
Eli Lilly and Company, Pfizer Inc., Dexcel Pharma, Teva Pharmaceuticals Industries Ltd., and Emergent Biosolutions, Inc. are key players operating in the periodontal therapeutics market.
The Asia Pacific is expected to grow at high revenue CAGR in the global periodontal therapeutics market.
Developing and approving new periodontal therapeutics may be subject to regulatory challenges, including lengthy approval processes, complex regulations, and high clinical trial and compliance costs. These regulatory challenges can hinder innovation in periodontal therapeutics and limit the availability of new treatment options for patients.
*Insights on financial performance are subject to the availability of information in the public domain